New findings support the use of RhoVac’s cancer vaccine in several...
Whilst waiting on the readout of the BRaVac phase IIb study, RhoVac continues to build its data package around the cancer vaccine candidate onilcamotide....
Cyxone focuses on the RA programme
First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK, and advanced...
Annexin´s CMO on patent strategy
Stockholm-based Annexin Pharmaceuticals has recently obtained FDA approval for the company's phase II study in RVO, a production patent in the US, and a...
Focus on company split for Respiratorius during Q4
Lund-based Respiratorius is currently undergoing an extensive transformation where the company’s two development projects are being separated. That process set the tone for the...
CombiGene’s new project manager on a broadened pipeline
In parallel with CombiGene’s continued development of drug candidate CG01 together with Spark Therapeutics, the company is investigating the terrain to in-license additional promising...
Promore Pharma aims to accelerate healing of venous leg ulcers
Peptide company Promore Pharma is undeniably in an exciting phase with two drug candidates in the field of wound treatment currently in late clinical...
Sprint Bioscience maintains focus on developing the portfolio
With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued...
Emplicure’s co-founder on the company’s next step
Since it was founded in 2014, Emplicure has transformed from being a company with potential and ambitions of going public to today having one...
Unchanged sales figures for Invent Medic in Q1
Invent Medic has started 2022 on the offence, with several new initiatives and focus on increasing sales of the two products in the Efemia...
Emplicure steams towards key milestones in Amp01 and Empli03
Emplicure’s report for the first quarter of 2022 puts the emphasis on the preparations for the pharmacokinetic study with the main project Empli03. The...
